Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
that is not owc news.
Ziv did Not leave. He was let go. FACT - He is being replaced by someone much more capable.
no. he is being replaced by a much more capable person for next phase of the company. FACT
I stand by what i said last week. The co is going to announce distribution - sales partnership any day. Great update from the company soon.
did you know we have 8 patents LOL
I am very impressed with this news. you will see why soon.
Cheers
he did his part. now bring in big gun to move co fwd. this is big.
on Ziv I was told...
Ziv did his part now someone new will handle this position as we are now in new phase. upgrading mgmt team here.
Hearing Ziv is being replaced with proven pharma guy. Would be huge. lets see.
low vol drop thanks!
really? on timing sometimes. but facts not.
There is a reason why I said I will not post for 6 months if we do not get it in 2-3 weeks.
best of luck to you.
FWIW....After speaking with my Merrill guy today and another industry source I can say with a great deal of confidence we will have something substantial coming in the next 2-3 weeks.
- A partnership - pharma
- A distribution deal - sales of our product with well known - worldwide co.
If we don't I will not post here for 6 months.
Take care.
could not disagree more. with what is coming no way
buy the dip here. enjoy. going way back up soon.
IF IF IF we get Licensing - partnership news after 10K we are $4+ I would think. Thoughts?
Buyout right now. No thanks. Licensing deal YES YES YES.
that would be awesome. I do not want a buyout right now tho. Partnership - Licensing YES
More from my Merrill guy:
after 10K we should get update on inquiry from Co - partnership - licensing deal(s) IMO. They have been talking - that is no secret. Not a buyout. A partnership on specific product ideas at TEVA needs new for diminishing pipeline.
I did not get it at first. I msgd him back and he said Teva dummy. More details soon. If you go back to the Dunn and Bradstreet stuff this does make sense. Now that OWCP is further along as a co
From my guy at Merrill:
guess who in talks partnering - licensing 2-3 products. think ugly sandals.
talk about low vol shaking tree here. gobble gobble
thanks for the 97's!!!!!!!!!
more from my guy at Merrill:
watch who is on bid rest of week and next few weeks. shares will be gobbled up. now that OWCP further along and proving up prod and launch. told you this is $10 sooner than u think
From my guy at Merrill Lynch:
take a look. big hitters like this taking positions on OWCP. and a good friend.
Todd Harrison?Verified account @todd_harrison
More
I like finding good stories, reputable management, few market-makers and ZERO institutional research. $OWCP
PR NEWS
OWC Pharmaceutical Research Corp OWCP:OTCQB
OWC Pharmaceutical Research Corp. Announces World-Wide Expression of Interest in its Cannabis-based Topical Cream for Treatment of Psoriasis and other Skin Disorders
PR Newswire
9:57 AM ET
OWC Pharmaceutical Research Corp. (OTCQB: OWCP), ("OWC" or the "Company"), an Israeli-based research company engaged in the development of cannabinoid-based therapies targeting a variety of different medical conditions and disorders, today announced it has received expressions of interest from the scientific and medical communities world-wide as a result of its recently announce positive preliminary clinical efficacy tests results of its topical cream to treat Psoriasis.
(Logo: http://mma.prnewswire.com/media/458036/OWC_Logo.jpg )
OWCP's scientific team, led by the renowned Dr. Yehuda Ba ruch, the Company's Chief Science Officer and OWC's Director of Research and Regulatory Affairs, and former Director of Israel's Ministry of Health Medical Management Division, previously reported trial results and concluded that post-application of OWC's unique, active cannabinoid-based topical cream formulation, there was up to 70% improvement in a variety of inflammation markers directly associated with Psoriasis. These promising results have led the Company to expand the size and scope of its clinical study and has led directly to OWC's receipt of continuing inquiries and expressions of interest from researchers world-wide for more information on the cannabinoid-based topical cream for treatment of psoriasis and our product's anticipated availability for use in the market.
The Company active ly protects its IP and will release the final results, relevant protocols and clinical data after the completion of the full BIO-DATA IP PROTECTION.
Mr. Ziv Turner, OWC's, Managing Director, commented, "As soon as we announced the efficacy results of our pre-clinical psoriasis treatment, OWC has continued to receive active inquiries from a variety of leading international scientific institutions in Countries like Germany, the Czech Republic, Hungary and more, that adopted or about to adopt MMJ bills. We are currently in negotiations for scientific and marketing cooperation agreements. In addition, we realistically expect product readiness for our topical cream in early Q3 2017 and, subject to regulatory approvals, federal and states laws we will be able to offer our topical cream to those w ho suffer from psoriasis."
Psoriasis is an autoimmune disease that causes red, scaly patches to appear on the skin, and can be associated with other serious health conditions, including diabetes, heart disease and depression. Skin cells in patients with psoriasis grow at an abnormally fast rate, causing a buildup of lesions that tend to burn and itch. While the real cause of psoriasis is not known, genetics are believed to play a major role in its development. According to the National Psoriasis Foundation, psoriasis affects 7.5 million people in the United States.
A wide and in-depth multi-layer clinical st udy on Psoriasis and psychological aspects is targeted to start next year, 2018, after collection of data from patients to carefully plan the targets of such a unique study that will show a combination of cannabinoids treatments for a specific disease. The study is carefully managed by Dr. Yehuda Baruch, the Company's CSO & Director of Research and Regulatory Affairs. Dr. Baruch comments, "We started safety phase at the hospital by this month, April 2017, and already planning a unique multi-center efficacy study. This is the natural development of the next generation of safe and tested cannabinoids treatments".
About OWC Pharmaceutical Research Corp.
OWC Pharmaceutical Research Corp., through its wholly-owned Israeli subsidiary, One World Cannabis Ltd., (collectively "OWC" or the "Company") conducts medical research and clinical trials to develop cannabis-based pharmaceuticals and treatments for conditions including multiple myeloma, psoriasis, fibromyalgia, PTSD, and migraines. OWC is also developing unique delivery systems for the effective delivery and dosage of medical cannabis. All OWC research is conducted at leading Israeli hospitals and scientific institutions, and led by internationally renowned investigators.
The Company's Research Division is focused on pursuing clinical trials evaluating the effectiveness of cannabinoids for the treatment of various medical conditions, while its Con sulting Division is dedicated to helping governments and companies navigate complex international cannabis regulatory frameworks. For more information, visit: http://www.owcpharma.com/
Notice Regarding Forward-Looking Statements
This news release contains "forward-looking statements" as that term is defined in Section 27A of the United States Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Statements in this press release, which are not purely historical, are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, filing patent applications, product development, and business strategy. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects and development stage companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk facto rs disclosure outlined in OWC Pharmaceutical Research Corp. (OTCQB: OWCP) periodic reports filed from time-to-time with the Securities and Exchange Commission.
Contact Information: In Israel: Mordechai Bignitz Chairman and CEO Email: mordechai.bignitz@owcpharma.com Tel: +972-(0)3-770-8526
SOURCE OWC Pharmaceutical Research Corp.
https://rt.prnewswire.com/rt.gif?NewsItemId=enUK201704057603&Transmission_Id=2017040 50957PR_NEWS_USPR_____enUK201704057603&DateId=20170405
Business Wire is a registered trademark of Business Wire. GlobeNewswire is a registered trademark of The NASDAQ OMX Group, Inc. PR Newswire is a registered trademark of PR Newswire Association, Inc.
Please do not reply to this e-mail from Markit On Demand. Markit On Demand and TD Ameritrade are separate unaffiliated companies and are not responsible for each other's service. For questions regarding your brokerage account, please contact TD Ameritrade Client Services at 1-800-669-3900.
To stop receiving this alert from TD Ameritrade, please click here to update your subscription settings. You may also unsubscribe from all of your alerts using the link above. As always, you can manage all of your alert settings by logging into your TD Ameritrade account and navigating to Research & Ideas > Alerts.
PR is coming
"Recent Clinical Tests Reflected up to 70% Improvement in Proliferation and Inflammation Markers Associated with Psoriasis"
lol. Early q3 vs late q2. hilarious
Perfect storm
Hell yes it is!
People will soon realize the significance of the Psoriasis breakthrough IMO. It will be spelled out for us.
best of luck with that
you should prob add another $1 to that